Company news

Entera Bio Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

August 19, 2024

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

August 8, 2024

Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected

July 31, 2024

Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024

June 2, 2024

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

May 14, 2024

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

May 12, 2024

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

May 9, 2024

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

April 7, 2024

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

March 25, 2024

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

March 19, 2024

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

March 7, 2024

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

March 3, 2024

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 29, 2024

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

January 2, 2024

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

December 25, 2023

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform

November 28, 2023

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

November 13, 2023

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

November 8, 2023

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

October 15, 2023

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

September 11, 2023

Entera Bio to Participate in Upcoming Investor Conferences

September 4, 2023

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

August 15, 2023

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

August 10, 2023

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

June 6, 2023

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

May 4, 2023

Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

May 2, 2023

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board

April 25, 2023

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

April 2, 2023

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

March 30, 2023

Entera Bio Regains Compliance with Nasdaq Listing Requirements

March 22, 2023

Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

February 14, 2023

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

February 12, 2023

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

November 9, 2022

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

October 5, 2022

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET

September 20, 2022

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 11, 2022

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

September 11, 2022

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

August 10, 2022

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

July 25, 2022

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

July 17, 2022

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities

June 16, 2022

Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy

May 15, 2022

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

May 11, 2022

Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics

May 4, 2022

Entera Bio to Report First Quarter 2022 Financial Results on May 12

April 27, 2022

Entera Bio to Present at 2022 Maxim Virtual Growth Conference

March 21, 2022

Entera Bio to Present at Aegis Virtual Conference on February 23rd

February 16, 2022

Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

January 3, 2022

Entera Bio Reports Third Quarter 2021 Financial Results

November 9, 2021

Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs

October 27, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.